Short Interest in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Rises By 76.7%

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 4,010,000 shares, a growth of 76.7% from the March 31st total of 2,270,000 shares. Based on an average trading volume of 2,450,000 shares, the days-to-cover ratio is presently 1.6 days.

Insider Activity

In other Aquestive Therapeutics news, insider Alexander Mark Schobel sold 50,000 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $6.00, for a total transaction of $300,000.00. Following the completion of the transaction, the insider now directly owns 984,476 shares in the company, valued at $5,906,856. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.39% of the stock is owned by company insiders.

Institutional Investors Weigh In On Aquestive Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Legato Capital Management LLC acquired a new stake in Aquestive Therapeutics in the 4th quarter valued at approximately $688,000. Armistice Capital LLC increased its position in shares of Aquestive Therapeutics by 314.5% during the 3rd quarter. Armistice Capital LLC now owns 4,800,000 shares of the company's stock worth $7,344,000 after purchasing an additional 3,642,000 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Aquestive Therapeutics by 238.8% during the 3rd quarter. Acadian Asset Management LLC now owns 550,484 shares of the company's stock worth $841,000 after purchasing an additional 388,017 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Aquestive Therapeutics by 14.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 247,828 shares of the company's stock worth $379,000 after purchasing an additional 30,898 shares during the last quarter. Finally, Jump Financial LLC acquired a new position in shares of Aquestive Therapeutics during the 4th quarter worth approximately $60,000. Institutional investors and hedge funds own 32.45% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently commented on AQST. Raymond James began coverage on Aquestive Therapeutics in a research report on Thursday, March 28th. They issued an "outperform" rating and a $7.00 price objective for the company. Piper Sandler initiated coverage on Aquestive Therapeutics in a report on Thursday, April 11th. They set an "overweight" rating and a $10.00 target price on the stock. JMP Securities raised their target price on Aquestive Therapeutics from $8.00 to $10.00 and gave the stock an "outperform" rating in a report on Friday, March 15th. Finally, HC Wainwright restated a "buy" rating and set a $9.00 target price on shares of Aquestive Therapeutics in a report on Friday, April 5th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $8.00.

Aquestive Therapeutics Trading Up 3.6 %

Shares of NASDAQ:AQST traded up $0.14 during trading on Friday, hitting $4.07. 2,920,434 shares of the company's stock traded hands, compared to its average volume of 2,193,878. Aquestive Therapeutics has a 52 week low of $1.19 and a 52 week high of $6.23. The company has a market cap of $298.33 million, a price-to-earnings ratio of -29.86 and a beta of 2.87. The company has a 50-day moving average price of $4.14 and a 200-day moving average price of $2.79.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last released its quarterly earnings data on Tuesday, March 5th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.04). The firm had revenue of $13.21 million during the quarter, compared to analyst estimates of $11.79 million. On average, analysts predict that Aquestive Therapeutics will post -0.36 earnings per share for the current fiscal year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.